

Switch to Dolutegravir-Abacavir-Lamivudine
STRIIVING Study

Switch to Dolutegravir-Abacavir-Lamivudine (DTG-ABC-3TC)

STRIIVING: Design

- **Background**


- Open-label, randomized study, phase 3 trial comparing switch to dolutegravir-abacavir-lamivudine (DTG-ABC-3TC) versus continuation of baseline ART

- **Inclusion Criteria** (n = 553)

- HIV RNA <50 copies/mL on ART
- Stable on current ART for ≥6 months
- No prior virologic failure
- HLA-B*5701 negative

- **Treatment Arms**


- Switch to DTG-ABC-3TC
- Continuation of baseline ART* x 24 weeks, then switch to DTG-ABC-3TC



*Baseline antiretroviral therapy (ART): 2 NRTIs + anchor drug (INSTI, NNRTI, or boosted PI)

Switch to Dolutegravir-Abacavir-Lamivudine (DTG-ABC-3TC) STRIIVING: Results

Week 24 and 48 Virologic Response



Switch to Dolutegravir-Abacavir-Lamivudine (DTG-ABC-3TC)

STRIIVING: Conclusions

Conclusions: “Data demonstrating non-inferiority of switching to ABC/DTG/3TC versus continuing current ART support ABC/DTG/3TC as an option when considering switch regimens in HIV-1-infected adults with stable viral suppression.”

Acknowledgments

The **National HIV Curriculum** is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling \$1,021,448 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

